GP Chemotherapy in Combination With Tislelizumab and Ociperlimab as First-line Treatment in Advanced BTC

NCT05019677 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Repeat registration

Conditions

Intrahepatic Cholangiocarcinoma

Interventions

DRUG: GP+PD-1+Tight

Sponsor

Fudan University